Register for your FREE account now and join the thousands of healthcare professionals who have depended on us for over 26 years for accurate, concise, and timely drug information.

Keep me logged in Forgot your password?

Please wait...

Please wait...

DIPRIVAN

Compare DIPRIVAN  to:
Compare
Compare

Generic Name for DIPRIVAN

Propofol 10mg/mL; emulsion for IV inj or infusion; contains egg lecithin, soy.

Legal Classification:

Rx

Pharmacological Class for DIPRIVAN

Sedative-hypnotic.

Manufacturer of DIPRIVAN

APP Pharmaceuticals

Indications for DIPRIVAN

Induction and maintenance of monitored anesthesia care (MAC) sedation; combined sedation and regional anesthesia; and ICU sedation of intubated, mechanically ventilated adult patients. Induction of general anesthesia in patients ≥3 years of age. Maintenance of general anesthesia in patients ≥2 months of age.

Adult dose for DIPRIVAN

See literature. Individualize. Allow 3–5 minutes between dose adjustments. General anesthesia induction (<55yrs): 40mg every 10 seconds until induction onset. Elderly, debilitated, ASA-PS III or IV, cardiac anesthesia, neurosurgery: 20mg every 10 seconds until induction onset. General anesthesia maintenance as infusion (<55yrs and neurosurgery): initially 100–200microgram/kg/min for 10–15 minutes, reduce to 50–100microgram/kg/min. Elderly, debilitated, ASA-PS III or IV: 50–100microgram/kg/min. Cardiac anesthesia: As the primary agent: 100–150microgram/kg/min; with primary opioid: 50–100microgram/kg/min. General anesthesia maintenance as intermittent bolus (<55yrs): increments of 20–50mg as needed. Initiation of MAC sedation: give by slow infusion of 100–150microgram/kg/min for 3–5 minutes or slow injection of 0.5mg/kg over 3–5 minutes followed immediately by maintenance infusion. Maintenance of MAC sedation (<55yrs): infuse 25–75microgram/kg/min (preferred) or give incremental boluses of 10mg or 20mg; elderly, debilitated, ASA-PS III or IV, neurosurgical patients: reduce dose by 20%. ICU sedation: initially infuse 5 microgram/kg/min for at least 5 minutes; increase in increments of 5–10microgram/kg/min over 5–10minutes until clinical effect is achieved. Maintenance: 5–50microgram/kg/min or higher; continue until 10–15 minutes prior to extubation. May give 10mg or 20mg bolus to rapidly increase depth of sedation in patients not at risk of hypotension.

Children's dosing for DIPRIVAN

Individualize. General anesthesia induction (3–16yrs): 2.5–3.5mg/kg given over 20–30 seconds. General anesthesia maintenance (2mos–16yrs): 125–300microgram/kg/min, decrease infusion rate if signs of light anesthesia are not present following the first ½ hour.

Contraindications for DIPRIVAN

Egg or soy product allergy.

Warnings/Precautions for DIPRIVAN

Should be administered only by persons trained in the administration of general anesthesia. Keep resuscitative equipment, artificial ventilation and oxygen readily available; maintain patency of the airway at all times. Initiate drug holiday and supplement lost zinc if infused for >5 days (esp. patients with burns, diarrhea, major sepsis). Hyperlipoproteinemia. Diabetic hyperlipemia. Pancreatitis. Seizure disorder. Increased intracranial pressure. Impaired cerebral circulation. Cardiac depression. Hemodynamically unstable. Correct fluid deficits before administration. Monitor cardiorespiratory status, renal function, triglycerides, serum zinc. Avoid abrupt cessation. American Society of Anesthesiologists Physical Status (ASA-PS) III or IV, elderly debilitated: avoid rapid bolus administration. Labor & delivery, nursing mothers: not recommended. Pregnancy (Cat.B).

Interactions for DIPRIVAN

Potentiation with volatile inhalational anesthetics (eg, enflurane, isoflurane, halothane), parental narcotics (eg, morphine, meperidine, fentanyl) or combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, choral hydrate, droperidol), other CNS depressants; reduce dose. Children: concomitant fentanyl may cause serious bradycardia.

Adverse Reactions for DIPRIVAN

Hypotension, bradycardia, inj site pain, apnea, propofol infusion syndrome with high-dose infusions (>5mg/kg/h for >48hrs); rare: anaphylaxis, phlebitis, thrombosis, perioperative myoclonia. Children: also movement, hypertension, rash, pruritis, tachycardia nodal, arrhythmia.

How is DIPRIVAN supplied?

Ready-to use vial (20mL, 50mL, 100mL)—1

Related Disease:

Anesthesia

Related Resources

Diclofenac Sodium 1% Gel Safe for Long-Term Treatment of Osteoarthritis in Elderly

May 19, 2012

Diclofenac sodium 1% gel is well tolerated for up to 1 year for the relief of osteoarthritis (OA) pain in patients both <65 years and ≥65 years of age, according to 12-month data presented at the American Pain Society's 31st Annual Scientific Meeting.

Gender, High DAS28-P Index Predictive of Pain in Early RA

May 18, 2012

For patients with rheumatoid arthritis (RA), female gender and having a high proportion of disease activity score (DAS28) attributable to patient-reported components (joint tenderness and visual analog score) (DAS28-P) at baseline are predictive of less improvement in pain at one year.

Bisphosphonates Cut Skeletal Morbidity in Multiple Myeloma

May 17, 2012

For patients with multiple myeloma, bisphosphonate treatment is associated with reduced pathological vertebral fractures, skeletal related events (SREs), and pain, but bisphosphonates do not appear to improve overall survival (OS), with the exception of zoledronate, which has been found to be superior to placebo and etidronate for improving OS.

Diclofenac Sodium 1% Gel Minimizes Drug-Drug Interaction-Related Adverse Events

May 17, 2012

Minimal systemic distribution of topical diclofenac sodium gel resulted in a lower incidence of major or moderate drug-drug interactions associated with oral diclofenac and reduced the risk of drug interaction-related adverse events. Study results were reported by Matthew Wieman, MD, from Endo Pharmaceuticals, John H. Peniston, DO, from Novartis Consumer Health, and colleagues at the American Pain Society's 31st Annual Scientific Meeting.

Vitamin D Deficiency Associated With Increased Osteoarthritis Symptoms and Reduced Pain Threshold

May 17, 2012

Study investigators presented data from the UPLOAD (Understanding Pain & Limitations in OsteoArthritic Disease) study at the American Pain Society's 31st Annual Scientific Meeting demonstrating that hydroxyvitamin D levels <25ng/mL were associated with an increase in osteoarthritis (OA) symptoms and a decreased threshold for pressure pain.

BC ARTHRITIS STRENGTH

Musculoskeletal Disorders > Arthritis/rheumatic disorders

Aspirin 742mg, caffeine 38mg, salicylamide 222mg; per powder; contains potassium 65mg/powder.

Updated: 11/11/2009

BONIVA

Musculoskeletal Disorders > Bone disorders

Ibandronate (as monosodium monohydrate) 150mg; tabs.

Updated: 4/20/2011

Ephedrine Sulfate Injection

Musculoskeletal Disorders > Muscle spasms

Ephedrine sulfate 50mg/mL; soln for IM, IV, or SC inj.

EXTRA STRENGTH BAYER

Musculoskeletal Disorders > Arthritis/rheumatic disorders

Aspirin 500mg; caplets; gelcaps.

TYLENOL ARTHRITIS

Musculoskeletal Disorders > Arthritis/rheumatic disorders

Acetaminophen 650mg; ext-rel caplets, geltabs.

ASTELIN

Respiratory Tract > Rhinitis/rhinorrhea (intranasal products)

Adverse reactions updated.

Updated: 5/8/2012

 

ATRAPRO ANTIPRURITIC HYDROGEL

Dermatological Disorders > Pruritus and dry skin

Monograph added.

Updated: 4/25/2012

 

ATRAPRO DERMAL SPRAY

Dermatological Disorders > Pressure/neuropathic ulcers

Monograph added.

Updated: 4/24/2012

 

B-NEXA

Nutrition > Vitamins/minerals/supplements

Monograph added.

Updated: 4/30/2012

 

CETAPHIL DERMACONTROL OIL CONTROL FOAM WASH

Dermatological Disorders > Cleansers

Monograph added.

Updated: 5/10/2012

 

Musculoskeletal Disorders > Arthritis/rheumatic disorders

NONSTEROIDAL ANTIINFLAMMATORY DRUGS (NSAIDs): Osteoarthritis, rheumatoid arthritis, and related disorders are inflammatory conditions that induce the production and release of ...
more »

Musculoskeletal Disorders > Bone disorders

BISPHOPHONATES: Bisphosphonates are specific inhibitors of osteoclast-mediated bone resorption. These agents act as chelators of calcium and have a high ...
more »

Musculoskeletal Disorders > Gout

Gout is caused by accumulation of uric acid in tissue as a result of underexcretion, overproduction, or both. Therapy for ...
more »

Musculoskeletal Disorders > Muscle spasms

α2-ADRENERGIC AGONISTS: Short-acting α2-adrenergic receptor agonists (eg, tizanidine) exert muscle relaxant effects by increasing presynaptic inhibition of spinal motor neurons. ...
more »

Osteoporosis Treatments

May 16, 2012

Osteoporosis treatment chart.

Muscle Spasm Treatments

March 09, 2012

Muscle spasm treatment chart with dosing regimens for muscle relaxants and other medications.

Arthritis Treatments: NSAIDS

January 12, 2012

NSAIDS (Non-steroidal anti-inflammatory drugs) indicated for the treatment of arthritis.

Arthritis Treatments: DMARDs and Other Immune Modulators

October 03, 2011

Dosing of DMARDS, TNF blockers, interleukin-1 receptor antagonists, interleukin-6 receptor inhibitors, selective costimulation modulators and CD20 antibodies for the treatment of arthritis.

Medications with Significant Anticholinergic Properties

October 01, 2009

Commonly prescribed medications that cause significant anticholinergic effect, plus a list of potential adverse consequences.

ClinicalJobAdvisor

Loading...

More Jobs

© 2012 Haymarket Media, Inc.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions